Targeted Therapy Showed Promise for Rare Blood Cancer
In a clinical trial analysis, patients with hard-to-treat Waldenström macroglobulinemia saw high response rates with a new drug.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies can safely accelerate the approval process for new cancer treatments?
Cellectar Biosciences reported that its investigational drug, iopofosine I 131, achieved significant response rates in patients with Waldenström macroglobulinemia who had previously failed BTK inhibitor therapy. These findings represent a potential path forward for individuals with this rare type of blood cancer who have run out of effective treatment options.
Why it matters
The analysis offers potential hope for those who are refractory or resistant to standard BTK inhibitor treatments, which are currently common in the clinical management of the disease. Developing therapies for this population is critical to improving outcomes for patients who have already cycled through multiple lines of prior treatment.
A Phase 2 clinical trial subset analysis evaluated the efficacy of iopofosine I 131 in patients who had received at least two prior lines of treatment. The study observed a major response rate of 79.2% and an overall response rate of 87.5%, with a response duration exceeding 16 months.
The players
Cellectar Biosciences
A pharmaceutical company headquartered in Florham Park, New Jersey, focused on developing targeted radiopharmaceuticals for cancer.
The details
Iopofosine I 131 is a targeted radiopharmaceutical designed to deliver radiation directly to cancer cells. By administering this treatment immediately after BTK inhibitor therapy, the study aimed to address the resistance mechanisms that often develop in patients with Waldenström macroglobulinemia. This approach seeks to kill malignant cells while minimizing damage to healthy tissues, providing a secondary intervention when conventional kinase inhibitors no longer suppress tumor growth.
Timeline
September 29, 2026: Cellectar Biosciences announced the clinical trial data.
October 14-16, 2026: The International Workshop for Waldenström Macroglobulinemia takes place in Palm Springs, California.
October 15, 2026: A poster presentation is scheduled for 4:00 PM.
Early 2027: Planned start for Phase 3 confirmatory trial dosing.
First half of 2027: Target for New Drug Application submission for accelerated approval.
Health Landscape
This research aligns with the broader medical effort to identify effective subsequent therapies for Waldenström macroglobulinemia following BTK inhibitor resistance. It underscores the current push toward specialized, targeted delivery systems in oncology to bypass traditional chemotherapy limitations.
Patients currently struggling with treatment-resistant blood cancers should discuss these preliminary trial findings with their oncologist to determine if future clinical trials might be appropriate for their care plan. It is vital to note that this therapy is still in development and not yet available for general clinical use.
The takeaway
This data suggests a potential new approach for patients who have exhausted standard treatment options for this rare blood cancer. Keep track of upcoming regulatory news regarding accelerated approval, and always consult with a hematologist-oncologist regarding new clinical trial eligibility.
What happens next
Cellectar Biosciences expects to begin dosing in a Phase 3 confirmatory trial in early 2027 and aims to submit a New Drug Application for accelerated approval during the first half of 2027.
Further reading
Explore the latest Cancer research and treatment developments for patients managing blood malignancies.
More information
For more on the drug's development, visit the Cellectar Biosciences company information page.
Live Poll
Do you trust that pharmaceutical companies can safely accelerate the approval process for new cancer treatments?
